1. Clinical & Scientific Overview
Ivabradine Hydrochloride (TIP-MED-000041, Reference Code [3.41]) is classified under
Cardiovascular & Antithrombotic Medicines (Ch 03) as a Selective Sinoatrial Funny-Current (If) Channel Inhibitor (Schedule H).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 03 [3.41], p. 41): Ivabrad (Torrent), Coralan (Servier), Bradia (Intas) — Strengths & Dosage Forms: Film-Coated Tablets: 5 mg, 7.5 mg; Dispersible/OD formulations
Film-Coated Tablets: 5 mg, 7.5 mg; Dispersible/OD formulations
3. Mechanism of Action & Pharmacodynamics
Selective Sinoatrial Funny-Current (If) Channel Inhibitor (Schedule H) acting on target receptor/enzyme pathways in Cardiovascular & Antithrombotic Medicines (Ch 03): clinical efficacy is mediated via Selective Sinoatrial Funny-Current (If) Channel Inhibitor (Schedule H) for Symptomatic HFrEF (LVEF <=35%) in normal sinus rhythm with resting HR >=70 bpm despite maximally tolerated Beta-blocker (or when Beta-blocker is contraindicated); chronic stable angina in sinus rhythm.
4. Therapeutic Indications & Evidence-Supported Uses
- Symptomatic HFrEF (LVEF <=35%) in normal sinus rhythm with resting HR >=70 bpm despite maximally tolerated Beta-blocker (or when Beta-blocker is contraindicated)
- chronic stable angina in sinus rhythm
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Start 5 mg PO BD with meals (Start 2.5 mg BD in patients >=75 years); after 2 weeks, adjust to 7.5 mg BD if HR >60 bpm, or reduce to 2.5 mg BD if HR <50 bpm or symptomatic bradycardia
Administration & Meal Timing: MUST be taken WITH MEALS (food delays absorption peak and ensures consistent bioavailability) | Morning & Evening WITH Breakfast & Dinner
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: No adjustment needed if CrCl >15 mL/min. Hepatic: Contraindicated in severe hepatic insufficiency (Child–Pugh C)
Renal: No adjustment needed if CrCl >15 mL/min. Hepatic: Contraindicated in severe hepatic insufficiency (Child–Pugh C)
Renal: No adjustment needed if CrCl >15 mL/min. Hepatic: Contraindicated in severe hepatic insufficiency (Child–Pugh C)
7. Contraindications, Precautions & High-Risk Warnings
- CONTRAINDICATED in resting HR <70 bpm prior to treatment, atrial fibrillation (ineffective in AF and increases AF risk!), sick sinus syndrome, 2nd/3rd-degree AV block, acute decompensated HF, severe hypotension (<90/50 mmHg), Child–Pugh C cirrhosis, pregnancy, and co-administration with Verapamil or Diltiazem!
Key Clinical Precautions: Renal: No adjustment needed if CrCl >15 mL/min. Hepatic: Contraindicated in severe hepatic insufficiency (Child–Pugh C)
8. Adverse Effects Profile
- Luminous visual phenomena / phosphenes (transient enhanced brightness in visual field in 14% of patients — resolves during therapy), sinus bradycardia
- Severe symptomatic bradycardia (<45–50 bpm), new-onset atrial fibrillation, 2nd/3rd-degree AV block
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- STRICTLY CONTRAINDICATED with Diltiazem, Verapamil, and Strong CYP3A4 Inhibitors (Clarithromycin, Erythromycin, Itraconazole, Fluconazole) — causes profound bradycardia! Caution with QTc-prolonging drugs (Amiodarone, Sotalol)
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Take twice daily with breakfast and dinner; brief flashes of light when moving from dark to bright rooms are harmless and usually fade; check pulse and report if <50 bpm or irregular
- Meal & Clock Timing Instruction: MUST be taken WITH MEALS (food delays absorption peak and ensures consistent bioavailability) (Morning & Evening WITH Breakfast & Dinner)
- Missed Dose Protocol: Take with next meal if remembered soon; never double dose
- Geriatric Dispensing Pearl: Always initiate at 2.5 mg (half of a 5 mg scored tablet) BD with meals in patients >=75 years
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Film-Coated Tablets: 5 mg, 7.5 mg; Dispersible/OD formulations
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 03 [3.41] (p. 41)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [3.43] Fenofibrate & Ezetimibe — PPAR-Alpha Agonist Fibrate & Intestinal NPC1L1 Cholesterol Absorp
- [3.44] Ticagrelor, Prasugrel, Dabigatran Etexilate & Enoxaparin Sodium — High-Alert P2Y12 Antiplatelets, Direct Thrombin Inhibitor & Low-M
- [3.4]-CMP1 Perindopril Erbumine IP — Angiotensin II Receptor Blocker (ARB) (Ester Prodrug)
- [3.31]-CMP2 Sumatriptan & Rizatriptan (Acute Migraine 5-HT1B/1D Agonists) — Non-Selective Beta-1 & Beta-2 Adrenoceptor Blocker (Schedule H |
